These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 19832854

  • 1. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E.
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
    [Abstract] [Full Text] [Related]

  • 2. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD, Polyzos SA, Avramidis A, Papatheodorou A, Terpos E.
    Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
    [Abstract] [Full Text] [Related]

  • 3. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Ballaouri I, Efstathiadou Z, Kita M, Avramidis A.
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 5. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 6. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB.
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [Abstract] [Full Text] [Related]

  • 7. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, Efstathiadou Z, Kita M, Avramidis A.
    Int J Clin Pract; 2008 Jun; 62(6):919-24. PubMed ID: 18422590
    [Abstract] [Full Text] [Related]

  • 8. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Pavlidou V, Koukoulis G, Avramidis A.
    Eur J Endocrinol; 2008 Mar; 158(3):411-5. PubMed ID: 18299476
    [Abstract] [Full Text] [Related]

  • 9. Endogenous intact PTH is suppressed during Teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis.
    Anastasilakis AD, Polyzos SA, Goulis DG, Slavakis A, Efstathiadou Z, Kita M, Koukoulis G, Avramidis A.
    Endocr J; 2008 Jul; 55(3):613-6. PubMed ID: 18520104
    [Abstract] [Full Text] [Related]

  • 10. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 11. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
    Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H.
    J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
    [Abstract] [Full Text] [Related]

  • 12. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A.
    Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
    [Abstract] [Full Text] [Related]

  • 13. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F, Ahmad AM, Ul-Haq M, Durham BH, Whittingham P, Fraser WD, Vora JP.
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [Abstract] [Full Text] [Related]

  • 14. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E.
    Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
    [Abstract] [Full Text] [Related]

  • 15. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    J Bone Miner Metab; 2005 Mar; 23(3):238-42. PubMed ID: 15838627
    [Abstract] [Full Text] [Related]

  • 16. Acute and chronic effect of teriparatide on glucose metabolism in women with established osteoporosis.
    Anastasilakis A, Goulis DG, Koukoulis G, Kita M, Slavakis A, Avramidis A.
    Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):108-11. PubMed ID: 17318770
    [Abstract] [Full Text] [Related]

  • 17. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

  • 19. Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis.
    Anastasilakis AD, Makras P, Pikilidou M, Tournis S, Makris K, Bisbinas I, Tsave O, Yovos JG, Yavropoulou MP.
    J Clin Endocrinol Metab; 2018 Mar 01; 103(3):1206-1213. PubMed ID: 29309589
    [Abstract] [Full Text] [Related]

  • 20. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.
    Gossiel F, Scott JR, Paggiosi MA, Naylor KE, McCloskey EV, Peel NFA, Walsh JS, Eastell R.
    J Clin Endocrinol Metab; 2018 Apr 01; 103(4):1302-1309. PubMed ID: 29365099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.